Generation Bio Co. GBIO
Institutional shares held
42.4 Million
70.4K
calls
700
puts
Total value of holdings
$16.5M
$27K
calls
$0
puts
Market Cap
$23M
59,011,200
Shares Out.
Institutional ownership
71.9%
# of Institutions
82
We take great care to ensure that the data presented and summarized in this overview for Generation Bio Co. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GBIO
View all-
Price T Rowe Associates Inc Baltimore, MD9.06MShares$3.53 Million0.0% of portfolio
-
Atlas Venture Life Science Advisors, LLC8.28MShares$3.23 Million0.97% of portfolio
-
Black Rock Inc. New York, NY3.29MShares$1.28 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY2.97MShares$1.16 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.62MShares$1.02 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY1.94MShares$758,5280.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.88MShares$733,4610.0% of portfolio
-
Bank Of America Corp Charlotte, NC1.29MShares$502,0020.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.11MShares$432,2840.0% of portfolio
-
Goldman Sachs Group Inc New York, NY1.09MShares$423,5780.0% of portfolio
Latest Institutional Activity in GBIO
Top Purchases
Top Sells
About GBIO
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at GBIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 15
2025
|
Kevin John Conway Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
173
-0.96%
|
$0
$0.37 P/Share
|
|
Apr 15
2025
|
Kevin John Conway Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
587
+3.15%
|
-
|
|
Apr 15
2025
|
Yalonda Howze CHIEF LEGAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
983
-4.98%
|
$0
$0.37 P/Share
|
|
Apr 15
2025
|
Yalonda Howze CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,347
+14.51%
|
-
|
|
Apr 15
2025
|
Antoinette Paone CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
468
-1.99%
|
$0
$0.37 P/Share
|
|
Apr 15
2025
|
Antoinette Paone CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,592
+6.33%
|
-
|
|
Apr 15
2025
|
Geoff Mcdonough PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,548
-0.11%
|
$0
$0.37 P/Share
|
|
Apr 15
2025
|
Geoff Mcdonough PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,274
+0.39%
|
-
|
|
Apr 15
2025
|
Phillip Samayoa CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
337
-0.26%
|
$0
$0.37 P/Share
|
|
Apr 15
2025
|
Phillip Samayoa CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,147
+0.88%
|
-
|
|
Jan 15
2025
|
Geoff Mcdonough PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,828
-0.14%
|
$0
$0.89 P/Share
|
|
Jan 15
2025
|
Geoff Mcdonough PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,274
+0.39%
|
-
|
|
Jan 15
2025
|
Antoinette Paone CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
552
-2.45%
|
$0
$0.89 P/Share
|
|
Jan 15
2025
|
Antoinette Paone CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,592
+6.61%
|
-
|
|
Jan 15
2025
|
Phillip Samayoa CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
398
-0.31%
|
$0
$0.89 P/Share
|
|
Jan 15
2025
|
Phillip Samayoa CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,147
+0.89%
|
-
|
|
Jan 15
2025
|
Yalonda Howze CHIEF LEGAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,160
-6.62%
|
$0
$0.89 P/Share
|
|
Jan 15
2025
|
Yalonda Howze CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,347
+16.03%
|
-
|
|
Jan 15
2025
|
Kevin John Conway Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
204
-1.16%
|
$0
$0.89 P/Share
|
|
Jan 15
2025
|
Kevin John Conway Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
587
+3.22%
|
-
|
Last 12 Months Summary
Buy / Acquisition
267K
Shares
From
8
Insiders
| Exercise of conversion of derivative security | 56.7K shares |
|---|---|
| Open market or private purchase | 211K shares |
Sell / Disposition
24K
Shares
From
8
Insiders
| Payment of exercise price or tax liability | 17.3K shares |
|---|---|
| Open market or private sale | 6.72K shares |